JNJ Ticker Curator

Bullish move: First National Bank & Trust Co. of Newtown ramped up its JNJ holdings by 72.3% in Q4 to 49,939 shares worth $10.335M—now its 8th-largest...

J&J discontinues promising CAR-T candidates JNJ-9530 and JNJ-4496—once eyed for >$5B peak sales—to focus on portfolio priorities amid evolving B-cell...

Pipeline Adjustments

• 🔥 CAR-T Halt: Johnson & Johnson halted development of CAR-T cell therapy in large B-cell lymphoma due to strategic...

Johnson & Johnson issued a statement on its investigational programs in large B-cell lymphoma, published April 30, 2026. Stock closed at 229.85 USD, up 1.10% that day and +11.07% YTD.

JNJ's enduring strength shines in the 2000-2026 pharma revenue rankings:

• 2000-2005: Battles Pfizer for #1 spot
• Survives patent cliffs hitting...

Johnson & Johnson is halting development of its CAR-T cell therapy for large B-cell lymphoma, citing a strategic business decision driven by portfolio priorities and the evolving treatment landscape. This signals a key oncology portfolio shift.

Spravato transforms depression care:

• Rewires brains with ketamine-derived spritzes, sparking highs, sobs, or dissociation—patients liken it to a...

• Internal promotion: Ryan Koors appointed VP, Investor Relations effective May 7, reporting to CFO Joseph Wolk; succeeds Darren Snellgrove heading to...

• Merck posts $16.3B revenue (+5%) led by Keytruda at $8B (+12%)
• BMS eyes $10.88B revenue, $1.43 EPS amid Eliquis patent pressure
• JNJ highlights...

Vivacity-MG3 OLE highlights sustained benefits for JNJ's IMAAVY (nipocalimab) in gMG patients:

• Symptom scores dropped: MG-ADL -6.47, QMG -5.97 at 96...

• Dividend increase: JNJ hiked payout to $1.24/share from $1.19 on Apr 15, reflecting confidence in earnings from Stelara/Darzalex; ex-date May 27,...

Key findings from Sen. Ron Johnson's probe into FDA vaccine oversight:

• 25 new safety signals uncovered for Pfizer, Moderna, and J&J shots, including...

J&J MedTech champions next-gen pulsed field ablation via VARIPULSE Pro's European launch, delivering ablations 5x faster than prior sequences with equivalent lesions and seamless CARTO 3 integration for familiar workflows. A big leap in cardiac tech.

Vivacity-MG3 updates reinforce nipocalimab's potential in myasthenia gravis:

• Continued benefits: Symptom improvement, stable disease management,...

Talc Litigation Escalation

• 🔥 Missouri Jury Verdict: A Missouri jury ordered Johnson & Johnson to pay $4.69 billion to 22 women alleging...

Quick peer check: JNJ shows stability vs volatile GSK.

• Prices/Changes: GSK $51.40 (-5.64%, vol 11.24M), JNJ $227.35 (-0.19%, vol 7.07M)
• Volumes vs...

Global talc cancer suits intensify for J&J: Missouri jury orders record $4.69 billion payout to 22 women over talc products; London court nears OK for thousands to join group claim. Watch for spillover risks.

Key trend signals for JNJ's stock rally:

• 62% surge powered by 6% revenue rise and 80% net income margin boost, despite 15% P/E dip
• 15%+ YTD gains...

• Bankruptcy rejection clears path: Texas court dismissed J&J's third plan in March 2025; no appeal, shifting to regular courts.
• Legal wins boost...

• FDA pilot monitors trial data live to slash approval timelines by targeting **45% paperwork